Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study

Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifuentes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi EY, Gross AE, Hand J, Heil EL, Hornback KM, Kaye KS, Khuu TV, Klatt ME, Kline EG, Kubat RC, Kufel WD, Lee JH, Lepak AJ, Lim A, Ludwig JM, Macdougall C, Majumdar A, Mathers AJ, McCreary EK, Miller WR, Monogue ML, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Pinargote P, Polk C, Satlin MJ, Satola SW, Shah S, Tamma PD, Tran TT, van Duin D, VanNatta M, Vega A, Venugopalan V, Veve MP, Wangchinda W, Witt LS, Wu JY, Pogue JM; PRECEDENT Network. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2024 Dec 16:S1473-3099(24)00648-0. doi: 10.1016/S1473-3099(24)00648-0. Epub ahead of print. PMID: 39701120.


Related Posts